Western blot analysis of ICAM-1, MCP-1, and FKN protein expression in retinas.

<p>Retinal cell extracts were prepared from animals treated as described in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0146438#pone.0146438.g001" target="_blank">Fig 1</a>. (A) Blots were probed with antibodies specific for ICAM-1, MCP-1, and FKN. β-actin was probed as a loading control. (B) The relative intensities of the bands in (A) were determined by ImageJ software and normalized to the expression of β-actin. Data are presented as the mean ± SD. *, <i>p</i> < 0.05 versus the Control group; #, <i>p</i> < 0.05 versus the Diabetes group.</p

Immunofluorescence staining of oxidative stress mediators in retinas.

<p>Retinal sections were prepared from Control, Diabetes, AST High, AST Low, or Lutein groups. Retinal oxidative damages were evaluated by immunofluorescence staining of (A) 8-hydroxy-2'-deoxyguanosine (8-OHdG) (B) nitrotysine, and (C) acrolein (original magnification 200×). (D) The relative density of immunostaining was defined as immunostaining index of control group. For quantitation of immunostaining, we first determined the immunostaining index, which could be measured and calculated from the following formula: Σ [(immunostaining density-threshold) × area (pixels)] / total cell number. Treatment with AST and lutein decreased the staining for nitrotysine, acrolein and 8-OHdG in the retinas compared with Diabetes group but the staining density of nitrotyrosine and acrolein in lutein group were significantly higher than control group. Data are presented as the mean ± SD. *, p < 0.05 versus the Control group; #, p < 0.05 versus the Diabetes group.</p

IHC staining of inflammatory mediators in retinas.

<p>Retinal sections were prepared from animals by each group. (A) Photomicrographs show immunocytochemical localization of ICAM-1, MCP-1, and FKN (original magnification 400×). (B) Images in (A) were quantified with Image-Pro software. Data are presented as the mean ± SD. *, <i>p</i> < 0.01 versus the Control group; #, <i>p</i> < 0.01 versus the Diabetes group.</p

mRNA levels of antioxidant defense enzymes in retinas.

<p>RNA was isolated from the retinas of rats by each group. (A) RNA was subjected to RT-PCR using gene-specific primers for HO-1, PRDX, Trx, and β-actin. (B) mRNA expression of HO-1, PRDX, and Trx, normalized to the expression of β-actin. Data are presented as the mean ± SD. *, <i>p</i> < 0.05 versus the Control group; #, <i>p</i> < 0.05 versus the Diabetes group.</p

mRNA levels of inflammatory mediators in retinas.

<p>(A) RNA was subjected to RT-PCR using gene-specific primers for ICAM-1, MCP-1, FKN, and β-actin. (B) mRNA expression of ICAM-1, MCP-1, and FKN, normalized to the expression of β-actin. Data are presented as the mean ± SD. *, <i>p</i> < 0.05 versus the Control group; #, <i>p</i> < 0.05 versus the Diabetes group.</p

Effect of AST and lutein on ICAM-1, MCP-1, and FKN expression in aqueous humors.

<p>Aqueous humor was isolated and pooled from the eyes of rats by each group. ICAM-1, MCP-1, and FKN levels were quantified by 3 repeat ELISA experiments. Data are presented as the mean ± SD. *, <i>p</i> < 0.05 versus the Control group; #, <i>p</i> < 0.05 versus the Diabetes group.</p

Evaluation of functional changes of the retina by electroretinography (ERG).

<p>The ERG were performed on untreated rats (Control) or STZ-induced diabetic rats treated for 8 weeks with normal saline (Diabetes), 3 mg/kg AST (AST High), 0.6 mg/kg AST (AST Low), or 0.5 mg/kg lutein (Lutein). The relative b-wave ratio was significantly decreased in the Diabetes, AST Low and Lutein groups compared with the Control group. The relative b-wave ratio in AST High group had no significant difference from Control group. The ratio in AST High group was significantly higher than that in the AST Low and the Lutein groups (<i>p</i> = 0.046 and <i>p</i> < 0.001). The data are expressed as the mean ± SD in 4 rats for each group (bar graph). *, <i>p</i> < 0.05 compared with the control group. #, <i>p</i> < 0.05 compared with the Diabetes group. Differences among groups were analyzed by one-way analysis of variance followed by Bonferroni’s test for multiple comparisons.</p

Immunohistochemical studies of cochlea.

<p>Representative radial section of caspase 3 staining in the cochlear basal turn (a,b). The intensity of caspase 3 stain was significantly tenser in the DIO group than in the control group in SG and SL (c). Representative radial section of poly(ADP-ribose) polymerase-1 (PARP-1) stain in the cochlear basal turn (d,e). The intensity of PARP-1 stain was significantly greater in the DIO group than in the control group in SG and SL (f). Representative radial section of apoptosis inducing factor (AIF) stain in the cochlear basal turn (g,h). The intensity of AIF stain was significantly tenser in the DIO group than in the control group in SG and SL (i).</p

Tooth extraction increases the risk of ONJ independent of the duration of alendronate therapy.

<p>The overall prevalence of ONJ in osteoporotic subjects taking oral alendronate is estimated at 0.34% (26/7625) which rises to 2.16% (11/509) after recent tooth extraction. The difference in the proportions of ONJ between subjects with and without recent tooth extraction is computed using the Fisher’s exact method. Tooth extraction is significantly associated with increased risk for ONJ among osteoporotic patients taking alendronate for 3 years or more (<i>P</i> = 0.012) and in those with less than 3 years of use (<i>P</i> <0.001), independent of drug duration. In addition, there is a greater proportion of ONJ among patients with BP duration of 3 years or more versus less than 3 years of use (0.92% versus 0.24%, <i>P</i> = 0.002), supporting the influence of BP duration on ONJ occurrence.</p

Comparisons of the both groups at the end of this study.

<p>Abbreviations: SD: standard deviation; DIO: diet-induced obesity; BW: body weight; TG: triglyceride; HDL-C: high-density lipoprotein cholesterol; ABR: auditory brainstem response.</p>*<p>Student's t-test.</p